Scientific Sessions Update: Studies Find No Increased Cancer Risk from Insulin Glargine

BREAKING NEWS: Some very good news today for people who use long-acting insulin glargine, also known by the brand name Lantus. Anna Baker reports the latest from Philadelphia.

Tweet this post    Share on Facebook    Email this post
This entry was posted in Life with Diabetes, Research, Scientific Sessions, Statistics, Stop Diabetes and tagged , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *


This site uses Akismet to reduce spam. Learn how your comment data is processed.